11 recruiting, 6 not yet recruiting, 5 unknown, 4 active not recruiting. 16 Phase 2, 8 Phase 3, 2 Not applicable, 2 Phase 1, 1 Phase 4.
Follow Radical Surgery: new trials by email Literature Review of Radical Surgery trials Research Report on Radical Surgery
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma Retlirafusp Alfa, Oxaliplatin, Capecitabine - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Tang-Du Hospital | 21 | 2026-08-30 | 2026-07-17 |
| Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis Immunotherapy Therapy, Radiation Therapy, Radical surgery - Malignant Tumors | Recruiting | Nanfang Hospital, Southern Medical University | 500 | 2026-05-29 | 2026-06-03 | |
| Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer Nivolumab, Ipilimumab (1mg/kg), PULSAR - Colorectal Cancer (MSI-H) | Phase 2 | Not yet recruiting | Fudan University | 114 | 2026-02-01 | 2026-02-11 |
| Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC Camrelizumab, Paclitaxel, carboplatin - Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms | Phase 2 | Not yet recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 50 | 2026-02-01 | 2026-02-10 |
| A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma Radical surgery, TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706) - Hepatocellular Carcinoma, Immunotherapy | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 48 | 2025-08-11 | 2025-08-20 |
| Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma Paclitaxel Polymersomes Combined with Carboplatin and Adebelimab, Radical Surgery - Resectable Mucosal Melanoma | Phase 2 | Recruiting | Sun Yat-sen University | 32 | 2025-03-20 | 2026-01-13 |
| Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC Neoadjuvant Chemotherapy, Immunotherapy, Radical surgery - Cervical Cancers | Phase 2 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 35 | 2025-03-15 | 2025-04-01 |
| Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers PD1/PDL1 antibody monotherapy, up to 24 weeks, Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks, Radical surgery - Gastric Cancer, Colon Cancer | Phase 2 | Recruiting | Peking University | 34 | 2024-09-13 | 2026-05-15 |
| Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Camrelizumab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-09-12 | 2025-03-20 |
| Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery - Esophageal Cancer, Immunotherapy | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2024-05-01 | 2025-05-30 |
| Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Camrelizumab, Cisplatin, Nab paclitaxel - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 / Phase 3 | Recruiting | Tongji Hospital | 440 | 2024-04-22 | 2024-10-30 |
| Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma three cycles (toripalimab + cetuximab + platinum), Radical surgery, Radiotherapy or chemoradiotherapy - Locally Advanced Hypopharyngeal Carcinoma | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 32 | 2024-01-18 | 2024-04-30 |
| Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer Radical surgery, Kidney sparing surgery+Postoperative radiotheray - Locally Advanced, Urothelial Carcinoma Ureter | Recruiting | Xuesong Li | 90 | 2023-11-10 | 2023-11-07 | |
| De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer Paclitaxel, trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Active not recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 186 | 2023-09-01 | 2026-02-27 |
| A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract Enfortumab Vedotin, Radical surgery - Urothelial Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 9 | 2023-06-02 | 2026-08-06 |
| A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer Sintilimab, IBI310&Sintilimab, Radical surgery - MSI-H | Phase 3 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 453 | 2023-05-25 | 2026-05-28 |
| Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma Camrelizumab, Apatinib Mesylate, Radical surgery - Hepatocellular Carcinoma, Immunotherapy | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 130 | 2023-01-31 | 2024-12-31 |
| Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma Doxorubicin+Ifosfamide+Anlotinib(AI+A), Radical Surgery - Retroperitoneal Sarcoma | Phase 4 | Enrolling by invitation | Peking University International Hospital | 102 | 2022-11-01 | 2023-05-12 |
| TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. Modified radical surgery, Radical surgery - Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | Unknown | Xiangya Hospital of Central South University | 124 | 2022-04-01 | 2023-05-24 |
Showing 20 of 33. Sign in to see all of them.
Uterine Cervical Neoplasms (5) · Mouth Neoplasms (4) · Stomach Neoplasms (4) · Carcinoma, Hepatocellular (3) · Squamous Cell Carcinoma of Head and Neck (3) · Colonic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1)
Sun Yat-sen University (4) · National Medical Research Radiological Centre of the Ministry of Health of Russia (2) · Shanghai Jiao Tong University School of Medicine (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Tongji Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Dimitri Christoforidis (1) · Eli Lilly and Company (1) · Emilio Ramos (1) · Eye & ENT Hospital of Fudan University (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Fudan University (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Memorial Sloan Kettering Cancer Center (1) · Nanfang Hospital, Southern Medical University (1)
China (24) · Russia (3) · Poland (1) · Spain (1) · Switzerland (1) · United States (1)
Ding Ma (2) · Yongxiang Xia (2) · Alexander Zakharenko, PhD (1) · Chenghua Luo, MD, PhD (1) · Dimitri Christoforidis (1) · Gennaro Galizia, MD (1) · Ilya Vervekin (1) · Jian Zhou, Doctor (1) · Jihong Liu, Ph. D (1) · Jihong Liu, Ph.D (1) · Keqin Hua, Doctor (1) · Lai-ping Zhong, MD, PhD (1) · Lai-ping Zhong, PHD (1)
PMID 31980034, PMID 32522771, PMID 36104359, PMID 37288582, PMID 41125112